Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 3/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518279 | 0.83 | HTR2A (0.41) | HTR2AHTR2CSLC6A4KDM1AKDM1B | |
| SCHEMBL14415683 | 0.78 | HTR2A (0.44) | HTR2AHTR2CSLC6A4KDM1AKDM1B | |
| Hydrochloric Acid SCHEMBL5517302 | 0.77 | HTR2A (0.43) | HTR2AHTR2CSLC6A4KDM1AKDM1B | |
| SCHEMBL14420427 | 0.74 | HTR2A (0.40) | HTR2AHTR2CSLC6A4KDM1AKDM1B | |
| SCHEMBL5524678 | 0.74 | HTR2A (0.45) | HTR2AHTR2CSLC6A4SRD5A1KDM1A | |
| SCHEMBL14415682 | 0.72 | HTR2A (0.58) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL31028086 | 0.71 | HTR2C (0.40) | HTR2AHTR2CSLC6A4HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL5518011 | 0.71 | HTR2A (0.57) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL8249889 | 0.69 | HTR2A (0.41) | HTR2AHTR2CSLC6A4SRD5A1KDM1A | |
| SCHEMBL14420428 | 0.69 | HTR2A (0.43) | HTR2AHTR2CSLC6A4HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7087765-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020004522-A1 | Nervous system disorders | NPS PHARMACEUTICALS, INC. | 2002-01-10 | — | — | US | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | HTR2A 390/4885HTR2C 696/4885MPO 4628/4885 |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | HTR2A 390/4885HTR2C 696/4885MPO 4628/4885 |
| US-20020004522-A1 | Nervous system disorders | HIF1A, PYGB, LDHB | HTR2A 1439/4885HTR2C 1777/4885MPO 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.